Abstract: An example system includes a plurality of AP devices configured to provide a wireless network at a site, the plurality of AP devices including a first AP device configured to determine a set of roaming candidates within the site for client devices connected to the first AP device, wherein the set of roaming candidates includes one or more AP devices of the plurality of AP selected according to a selection criteria; in response to establishing a connection with a client device, cache a key associated with the client device in the memory of the first AP device; generate a packet with the key associated with the client device, and a list of APs that includes one or more identifiers of the one or more AP devices within the set of roaming candidates for the first AP device; and transmit the packet to the plurality of AP devices at the site.

Abstract: Techniques are described that enable onboarding of a plurality of heterogeneous client devices with secure access to a wireless network using a network management system (NMS). The NMS has a memory to store a plurality of private pre-shared keys (PPSKs), where each PPSK is provisioned for a particular client device or a particular group of client devices. In response to a key lookup request from an access point (AP) device for a client device, the NMS performs a key lookup and, in response to identifying a PPSK provisioned for the client device, authenticates the client device to access the wireless network via the AP device. The NMS then manages one or more of tracking the client device, policy application to the client device, or handling of network traffic from the client device while connected to the wireless network using the PPSK as an identifier of the client device.

Abstract: Mechanisms are provided to implement a genomic database curation (GDC) system. The GDC system generates a ground truth database based on a training subset of datasets from an uncurated large scale genomic database, and label metadata for the training subset. The GDC system trains at least one classification engine of the GDC system based on the training subset and the ground truth database at least by performing a machine learning operation on the at least one classification engine. The GDC system automatically applies the at least one trained classification engine on the uncurated large scale genomic database to generate an automatically curated large scale genomic database. A meta-classifier engine generates an output specifying at least one of significant gene signatures or gene pathways for at least one of diseases or drug agents based on the automatically curated large scale genomic database.

Abstract: Embodiments of the present invention are directed to a computer-implemented method for generating a framework for analyzing adverse drug reactions. A non-limiting example of the computer-implemented method includes receiving to a processor, a plurality of drug chemical structures. The non-limiting example also includes receiving, to the processor, a plurality of known drug-adverse drug reaction associations. The non-limiting example also includes constructing, by the processor, a deep learning framework for each of a plurality of adverse drug reactions based at least in part upon the plurality of drug chemical structures and the plurality of known adverse-drug reaction associations.

Abstract: Embodiments of the present invention are directed to a computer-implemented method for generating a framework for analyzing adverse drug reactions. A non-limiting example of the computer-implemented method includes receiving to a processor, a plurality of drug chemical structures. The non-limiting example also includes receiving, to the processor, a plurality of known drug-adverse drug reaction associations. The non-limiting example also includes constructing, by the processor, a deep learning framework for each of a plurality of adverse drug reactions based at least in part upon the plurality of drug chemical structures and the plurality of known adverse-drug reaction associations.

Abstract: Embodiments of the present invention disclose a method, a computer program product, and a computer system for predicting drug and disease interactions. A computer identifies one or more drug similarity measures between one or more drugs and one or more disease similarity measures between one or more diseases. In addition, the computer identifies one or more interactions between the one or more drugs and the one or more diseases, then calculates one or more drug-disease feature vectors based on the one or more interactions, the one or more drug similarity measures, and the one or more disease similarity measures. Furthermore, the computer calculates a first probability indicating whether a first drug of the one or more drugs will interact with a first disease of the one or more diseases based on a model, wherein the model is trained based on the one or more drug-disease feature vectors.

Abstract: Mechanisms are provided for implementing a framework to learn multiple drug-adverse drug reaction associations. The mechanisms receive and analyze patient electronic medical record data and adverse drug reaction data to identify co-occurrences of references to drugs with references to adverse drug reactions (ADRs) to thereby generate candidate rules specifying multiple drug-ADR relationships. The mechanisms filter the candidate rules to remove a subset of one or more rules having confounder drugs specified in the subset of one or more candidate rules, and thereby generate a filtered set of candidate rules. The mechanisms further generate a causal model based on the filtered set of candidate rules. The causal model comprises, for each ADR in a set of ADRs, a corresponding set of one or more rules, each rule specifying a combination of drugs having a causal relationship with the ADR.

Abstract: Mechanisms are provided for implementing a framework to learn multiple drug-adverse drug reaction associations. The mechanisms receive and analyze patient electronic medical record data and adverse drug reaction data to identify co-occurrences of references to drugs with references to adverse drug reactions (ADRs) to thereby generate candidate rules specifying multiple drug-ADR relationships. The mechanisms filter the candidate rules to remove a subset of one or more rules having confounder drugs specified in the subset of one or more candidate rules, and thereby generate a filtered set of candidate rules. The mechanisms further generate a causal model based on the filtered set of candidate rules. The causal model comprises, for each ADR in a set of ADRs, a corresponding set of one or more rules, each rule specifying a combination of drugs having a causal relationship with the ADR.

Abstract: A mechanism is provided in a data processing system comprising at least one processor and at least one memory, the at least one memory comprising instructions executed by the at least one processor to cause the at least one processor to implement a drug response estimation engine. The drug response estimation engine receives real-world evidence for a plurality of patients. A patient similarity network builder component executing within the drug response estimation engine builds a patient similarity network. A regression analysis component executing within the drug response estimation engine builds a network localized regression analysis approach. A patient clustering component executing within the drug response estimation engine groups patients based on demographics and comorbidities to form a plurality of patient clusters.

Abstract: Mechanisms are provided for implementing a framework to learn multiple drug-adverse drug reaction associations. The mechanisms receive and analyze patient electronic medical record data and adverse drug reaction data to identify co-occurrences of references to drugs with references to adverse drug reactions (ADRs) to thereby generate candidate rules specifying multiple drug-ADR relationships. The mechanisms filter the candidate rules to remove a subset of one or more rules having confounder drugs specified in the subset of one or more candidate rules, and thereby generate a filtered set of candidate rules. The mechanisms further generate a causal model based on the filtered set of candidate rules. The causal model comprises, for each ADR in a set of ADRs, a corresponding set of one or more rules, each rule specifying a combination of drugs having a causal relationship with the ADR.

Abstract: Mechanisms are provided that implement a plurality of heterogeneous causality models and a metaclassifier for predicting a likelihood of causality between a drug and an adverse event (AE). The plurality of heterogenous causality models process drug information for the drug to generate a plurality of risk predictions for a drug and AE pair. The risk predictions include at least one of a risk score or a risk label indicating a probability of the AE occurring with use of the drug. The plurality of heterogenous causality models provide the risk predictions, associated with the drug and AE pair, to a metaclassifier which generates a single causality score value indicative of a probability of causality between the drug and the AE, of the drug and AE pair, based on an aggregation of the risk predictions from the plurality of heterogenous causality models. The metaclassifier outputs the single causality score value in association with information identifying the drug and AE pair.

Abstract: Mechanisms are provided that implement a plurality of heterogeneous causality models and a metaclassifier for predicting a likelihood of causality between a drug and an adverse event (AE). The plurality of heterogenous causality models process drug information to generate a plurality of risk predictions for a drug and AE pair. The risk predictions include a risk score or a risk label indicating a probability of the AE occurring with use of the drug. The plurality of heterogenous causality models provide risk predictions, associated with the drug and AE pair, to a metaclassifier which generates a single causality score value indicative of a probability of causality between the drug and the AE, of the drug and AE pair, based on an aggregation of the risk predictions from the plurality of heterogenous causality models. The metaclassifier outputs the single causality score value in association with information identifying the drug and AE pair.

Abstract: A mechanism is provided in a data processing system comprising at least one processor and at least one memory, the at least one memory comprising instructions executed by the at least one processor to cause the at least one processor to implement a drug response estimation engine. The drug response estimation engine receives real-world evidence for a plurality of patients. A patient similarity network builder component executing within the drug response estimation engine builds a patient similarity network. A regression analysis component executing within the drug response estimation engine builds a network localized regression analysis approach. A patient clustering component executing within the drug response estimation engine groups patients based on demographics and comorbidities to form a plurality of patient clusters.

Abstract: A mechanism computes a discounted health variable with a penalty for deviating from clinical guidelines based on a distance function representing an allowed deviation from the clinical guidelines, applies reinforcement learning techniques on the discounted health variable to generate a reinforcement learning (RL) model for generating dynamic treatment regimes, and determines, for a patient for a plurality of times, a next action in a treatment regime using the RL model with no distance function, an optimal next action in the treatment regime with allowed deviation from the guidelines, and a next action in the treatment regime that adheres to the guidelines. The mechanism generates an outcome output display based on the determined next action in a treatment regime using the RL model with no distance function, optimal next action in the treatment regime with allowed deviation from the guidelines, and next action in the treatment regime that adheres to the guidelines.

Abstract: Embodiments of the present invention disclose a method, a computer program product, and a computer system for predicting drug and food interactions. A computer identifies one or more drug similarity measures between one or more drugs and one or more food similarity measures between one or more foods. In addition, the computer identifies one or more interactions between the one or more drugs and the one or more foods, then calculates one or more drug-food feature vectors based on the one or more interactions, the one or more drug similarity measures, and the one or more food similarity measures. Furthermore, the computer calculates a first probability indicating whether a first drug of the one or more drugs will interact with a first food of the one or more foods based on a model, wherein the model is trained based on the one or more drug-food feature vectors.

Abstract: Mechanisms are provided to implement a genomic database curation (GDC) system. The GDC system generates a ground truth database based on a training subset of datasets from an uncurated large scale genomic database, and label metadata for the training subset. The GDC system trains at least one classification engine of the GDC system based on the training subset and the ground truth database at least by performing a machine learning operation on the at least one classification engine. The GDC system automatically applies the at least one trained classification engine on the uncurated large scale genomic database to generate an automatically curated large scale genomic database. A meta-classifier engine generates an output specifying at least one of significant gene signatures or gene pathways for at least one of diseases or drug agents based on the automatically curated large scale genomic database.

Abstract: Embodiments of the present invention disclose a method, a computer program product, and a computer system for predicting drug and food interactions. A computer identifies one or more drug similarity measures between one or more drugs and one or more food similarity measures between one or more foods. In addition, the computer identifies one or more interactions between the one or more drugs and the one or more foods, then calculates one or more drug-food feature vectors based on the one or more interactions, the one or more drug similarity measures, and the one or more food similarity measures. Furthermore, the computer calculates a first probability indicating whether a first drug of the one or more drugs will interact with a first food of the one or more foods based on a model, wherein the model is trained based on the one or more drug-food feature vectors.

Abstract: Embodiments of the present invention disclose a method, a computer program product, and a computer system for predicting drug and disease interactions. A computer identifies one or more drug similarity measures between one or more drugs and one or more disease similarity measures between one or more diseases. In addition, the computer identifies one or more interactions between the one or more drugs and the one or more diseases, then calculates one or more drug-disease feature vectors based on the one or more interactions, the one or more drug similarity measures, and the one or more disease similarity measures. Furthermore, the computer calculates a first probability indicating whether a first drug of the one or more drugs will interact with a first disease of the one or more diseases based on a model, wherein the model is trained based on the one or more drug-disease feature vectors.

Abstract: Link prediction for biomedical entities. A neural network is trained using known associations between biomedical entities, including their vector representations and additional information-carrying content describing the biomedical entities. The trained network infers or predicts unobserved associations between two entities.

Abstract: Mechanisms are provided for implementing a framework to learn multiple drug-adverse drug reaction associations. The mechanisms receive and analyze patient electronic medical record data and adverse drug reaction data to identify co-occurrences of references to drugs with references to adverse drug reactions (ADRs) to thereby generate candidate rules specifying multiple drug-ADR relationships. The mechanisms filter the candidate rules to remove a subset of one or more rules having confounder drugs specified in the subset of one or more candidate rules, and thereby generate a filtered set of candidate rules. The mechanisms further generate a causal model based on the filtered set of candidate rules. The causal model comprises, for each ADR in a set of ADRs, a corresponding set of one or more rules, each rule specifying a combination of drugs having a causal relationship with the ADR.